NDAINTRAVENOUSSOLUTION
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
DEXMEDETOMIDINE HYDROCHLORIDE (dexmedetomidine) by R-Pharm US is 2 -adrenergic agonist with sedative properties. Approved for sedation, delirium, anesthesia and 5 more indications. First approved in 2015.
Drug data last refreshed 20h ago
Mechanism of Action
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity was observed in animals following slow intravenous infusion of low and medium doses (10 mcg/kg to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (greater than or equal…
Indications (8)
Worked on DEXMEDETOMIDINE HYDROCHLORIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.